Eli Lilly reported full results from its phase 2 SYNERGY-MASH trial of GLP-1 and GIP agonist tirzepatide – already on the market as Mounjaro for diabetes and Zepbound for obesity – in biopsy ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Continue » Lilly's Mounjaro and Zepbound, which share the same generic drug (tirzepatide ... phase 2 clinical studies as a potential treatment for metabolic-associated steatohepatitis (MASH ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during the Phase ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Tirzepatide is the active ingredient in Lilly weight-loss drug Zepbound and the diabetes drug Mounjaro. Related Experimental Eli Lilly weight loss drug proves promising for type 2 diabetics Eli ...

New data documented dramatic shifts in prescribing for both type 2 diabetes (T2D) and weight loss, particularly with the uptake of tirzepatide (Lilly ... progressing into phase 3 trials and ...